Announced Thu, 5 Nov, 2026 · 17:38 IST
Molbio Q2 FY27 sales fall sharply; FY27 growth guidance retained
MOLBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reactionminutes from the announcement price · days from the prior close
-4.1%Reaction day
₹1404.50
prior close
₹1350.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending
Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-2.0
10m
-2.7
15m
-3.3
30m
-1.5
Sessions after the filingfrom the prior close
StockMarketvs market
Reaction day
-4.1pendingpending
Next day
———
2d
———
3d
———
4d
———
5d
———
1w
———
15d
———
1m
———
2m
———
3m
———
UpDownMarket · Nifty Microcap 250Pending
Minute windows have no benchmark: there is no intraday index history to compare against.
AI summary
Molbio Diagnostics reported Q2 FY27 total income of ₹264.8 crore versus ₹581.4 crore a year earlier, as rate-contract negotiations delayed sales for about 1 to 1.5 months. H1 total income was ₹676.3 crore versus ₹681.8 crore. Q2 EBITDA was ₹49.7 crore and net profit ₹7.7 crore, with margins of 18.8% and 2.9%. Management retained its 25% FY27 revenue growth target.
Likely market impact
Q2 profit and margins fell, creating near-term pressure. Management expects 25% FY27 revenue growth, but recovery depends on contract renewals.